EUVIMEDEUVIMED entdecken
Kohortenstudie

Associations Between Midlife Anticholinergic Medication Use and Subsequent Cognitive Decline: A British Birth Cohort Study

Mark J Rawle iD, Wallis C Y Lau, Arturo Gonzalez-Izquierdo, Praveetha Patalay, Marcus Richards, Daniel Davis

Drugs & Aging · 2024

DOI: 10.1007/s40266-024-01116-x ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Drugs & Aging, 2024. Verfasst von Mark J Rawle und 5 weiteren Autor:innen. Beteiligte Einrichtung: MRC Unit for Lifelong Health and Ageing at UCL, London, UK. m.rawle@ucl.ac.uk. Hauptthemen laut MEDLINE: Cholinergic Antagonists, Cognitive Dysfunction. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 39 Literaturangaben. Gefördert von: Medical Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Anticholinergic medication use is associated with cognitive decline and incident dementia. Our study, a prospective birth cohort analysis, aimed to determine if repeated exposure to anticholinergic medications was associated with greater decline, and whether decline was reversed with medication reduction. METHODS: From the Medical Research Council (MRC) National Survey of Health and Development, a British birth cohort with all participants born in a single week of March 1946, we quantified anticholinergic exposure between ages 53 and 69 years using the Anticholinergic Cognitive Burden Scale (ACBS). We used multinomial regression to estimate associations with global cognition, quantified by the Addenbrooke's Cognitive Examination, 3rd Edition (ACE-III). Longitudinal associations between ACBS and cognitive test results (Verbal memory quantified by the Word Learning Test [WLT], and processing speed quantified by the Timed Letter Search Task [TLST]) at three time points (age 53, 60-64 and 69) were assessed using mixed and fixed effects linear regression models. Analyses were adjusted for sex, childhood cognition, education, chronic disease count and severity, and mental health symptoms. RESULTS: Anticholinergic exposure was associated cross-sectionally with lower ACE-III scores at age 69, with the greatest effects in those with high exposure at ages 60-64 (mean difference - 2.34, 95% confidence interval [CI] - 3.51 to - 1.17). Longitudinally, both mild-moderate and high ACBS scores were linked to lower WLT scores, again with high exposure showing larger effects (mean difference with contemporaneous exposure - 0.90, 95% CI - 1.63 to - 0.17; mean difference with lagged exposure - 1.53, 95% CI - 2.43 to - 0.64). Associations remained in fixed effects models (mean difference with contemporaneous exposure -1.78, 95% CI -2.85 to - 0.71; mean difference with lagged exposure - 2.23, 95% CI - 3.33 to - 1.13). Associations with TLST were noted only in isolated contemporaneous exposure (mean difference - 13.14, 95% CI - 19.04 to - 7.23; p < 0.01). CONCLUSIONS: Anticholinergic exposure throughout mid and later life was associated with lower cognitive function. Reduced processing speed was associated only with contemporaneous anticholinergic medication use, and not historical use. Associations with lower verbal recall were evident with both historical and contemporaneous use of anticholinergic medication, and associations with historical use persisted in individuals even when their anticholinergic medication use decreased over the course of the study.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cholinergic AntagonistsCognitive DysfunctionHumansMiddle AgedMaleFemaleAgedBirth CohortUnited KingdomCohort StudiesCognitionLongitudinal StudiesCross-Sectional StudiesProspective Studies

Substanzen

Cholinergic Antagonists

Autor:innen und Institutionen

  • MRC Unit for Lifelong Health and Ageing at UCL, London, UK. m.rawle@ucl.ac.uk.
  • Academic Centre for Healthy Ageing (ACHA) @ Whipps Cross University Hospital, Barts Health NHS Trust, Whipps Cross Road, London, E11 1NR, UK. m.rawle@ucl.ac.uk.
  • Research Department of Practice and Policy, School of Pharmacy, UCL, London, UK.
  • Centre for Medicines Optimisation Research and Education, University College London Hospitals NHS Foundation Trust, London, UK.
  • Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, Centre for Safe Medication Practice and Research, The University of Hong Kong, Pok Fu Lam, Hong Kong.
  • Laboratory of Data Discovery for Health (D24H), Hong Kong Science Park, Pak Shek Kok, Hong Kong.

ORCID-Profile: Mark J Rawle

Förderung

  • Medical Research Council

Zitieren

APA

Rawle, M. J., Lau, W. C. Y., Gonzalez-Izquierdo, A., Patalay, P., Richards, M., & Davis, D. (2024). Associations Between Midlife Anticholinergic Medication Use and Subsequent Cognitive Decline: A British Birth Cohort Study. Drugs & Aging. https://doi.org/10.1007/s40266-024-01116-x

Vancouver

Rawle MJ, Lau WCY, Gonzalez-Izquierdo A, Patalay P, Richards M, Davis D. Associations Between Midlife Anticholinergic Medication Use and Subsequent Cognitive Decline: A British Birth Cohort Study. Drugs & Aging. 2024. doi:10.1007/s40266-024-01116-x

BibTeX
@article{Rawle2024,
  author = {Rawle, Mark J and Lau, Wallis C Y and Gonzalez-Izquierdo, Arturo and Patalay, Praveetha and Richards, Marcus and Davis, Daniel},
  title = {Associations Between Midlife Anticholinergic Medication Use and Subsequent Cognitive Decline: A British Birth Cohort Study},
  journal = {Drugs & Aging},
  year = {2024},
  doi = {10.1007/s40266-024-01116-x}
}
Kostenlos starten →